| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Sep'18 | Jun'18 |
|---|---|---|---|---|---|---|
Operating expenses: | ||||||
Research and development | ||||||
8,791 | 13,138 | 13,885 | 5,960 | 4,063 | 1,253 | 8,420 |
General and administrative | ||||||
3,588 | 3,083 | 2,424 | 1,649 | 1,449 | 474 | 242 |
Total operating expenses | ||||||
12,379 | 16,221 | 16,309 | 7,609 | 5,512 | 1,727 | 8,662 |
Loss from operations | ||||||
-12,379 | -16,221 | -16,309 | -7,609 | -5,512 | -1,727 | -8,662 |
Other income (expense): | ||||||
Interest income | ||||||
493 | - | - | - | 166 | - | - |
Change in fair value of preferred stock tranche obligation | ||||||
- | - | - | - | - | 8,400 | - |
Change in fair value of anti-dilution right liability | ||||||
- | - | - | - | - | 1,021 | 11 |
Other expenses | ||||||
- | - | - | - | 16 | - | - |
Total other income, net | ||||||
493 | 610 | 755 | 381 | 150 | -9,421 | -11 |
Net loss | ||||||
-11,886 | -15,611 | -15,554 | -7,228 | -5,362 | -11,148 | -8,673 |
Net unrealizable gain on marketable securities | ||||||
51 | - | - | - | - | - | - |
Comprehensive loss | ||||||
-11,835 | - | - | - | -5,362 | - | - |
Accretion of redeemable convertible preferred stock to redemption value | ||||||
- | - | - | - | - | 251 | 70 |
Net loss attributable to common stockholders | ||||||
- | - | -15,554 | -7,228 | - | -11,399 | -8,743 |
Net loss per common share, basic and diluted | ||||||
-0.42 | 31.77 | -0.56 | -2.21 | -31.90 | -89.66 | -94.86 |
Weighted-average number of shares used in computing net loss per common share, basic and diluted | ||||||
28,499 | 28,821 | 28,024 | 3,268 | 168 | 127 | 92 |